ImmuPharma Commences Trading on Stuttgart Exchange

RNS Number : 8448Y

Immupharma PLC

28 February 2013

 



FOR IMMEDIATE RELEASE

28 FEBRUARY 2013

RNS REACH

ImmuPharma PLC 

Commences Trading on the Stuttgart Stock Exchange

ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announces that it has been informed by Baader Bank AG that its shares are now being traded on the third segment  of the Stuttgart Stock Exchange.

Baader Bank AG has experience and expertise for trading in German and non-German securities at Germany's leading stock exchanges in Frankfurt, Berlin-Bremen, Munich and Stuttgart. They currently have more than 9,000 stocks from 56 countries including Coca-Cola, Citigroup, Sony and Singapore Airlines.

Dimitri Dimitriou, Chief Executive Officer of ImmuPharma commented: "We are delighted that we have further expanded our footprint into Europe with our shares now being traded on the Stuttgart Exchange. This should help dovetail efforts with our similar open market listing 'Tradegate' on the Berlin Exchange and we are confident that through these secondary European listings they will help support our UK Listing and assist in continuing to extend and strengthen our investor base."

Ends

For further information please contact:

ImmuPharma plc	+ 44 (0) 20 7152 4080
Dimitri Dimitriou, Chief Executive Officer
Dr Robert Zimmer, President and Chief Scientific Officer
Richard Warr, Chairman
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
Panmure, Gordon & Co., NOMAD & Broker	[phone]
Fred Walsh
Hannah Woodley

Notes to Editors

ImmuPharma

ImmuPharma is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need.  ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents.  The Company's most advanced drug candidate, Lupuzor^TM a potential blockbuster drug for Lupus, a chronic autoimmune disease has recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and "Fast Track" designation.  The Company's second potential blockbuster compound in cancer "IPP-204106" is completing  a new Phase I/ II clinical trial with the next generation of "polyplexed Nucant".  ImmuPharma was founded and is led by a commercially focused Board and management team with extensive experience. For more information on ImmuPharma please go to: www.immupharma.com.

About Baader Bank:
Baader Bank is one of Germany's leading investment banks and the market leader in trading of financial instruments. In investment banking, it develops financing solutions for companies in German-speaking countries. The bank offers institutional investors comprehensive services in marketing and trading of equities, bonds, and derivatives. As a market maker/specialist, Baader Bank is responsible for pricing more than 700,000 exchange-traded and OTC securities. For more information on Baader Bank please go to: www.baaderbank.de

 

END

 

 

NRALLFLAFEIDFIV